BioSpace News Archive

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 24 th Annual Meeting taking place virtually on May 11-14, 2021. Oral presentations include the first reporting on the company’s novel capsid technology.

Cincinnati Children’s Hospital Medical Center recently completed 100 prenatal surgical repairs to help improve the outcomes for babies with spina bifida, a rare birth defect that occurs when bones in the spine do not fully form during early pregnancy.

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced four upcoming oral presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually between May 11th to May 14th, 2021.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been recognized by the prestigious Great Place to Work® Institute as among the best places to work in the United Kingdom, Spain, Italy and Germany.

PetVivo Holdings, Inc. an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the United States Patent and Trademark Office has issued a patent related to the Company’s proprietary encapsulated or coated stent systems.

-- Conference Call Scheduled for Wednesday, May 5, 2021 at 4:30 p.m. ET --

ESSA Pharma Inc. (Nasdaq: EPIX) a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial collaboration and supply agreement with Bayer

- Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa -

Deciphera Pharmaceuticals, Inc. to Present at the Truist Securities Life Sciences Summit

Bristol Myers Squibb to Take Part in the 7 th Annual Truist Life Sciences Summit